Clinical & Experimental Immunology · 1990 · 170 citations · 23 references
Life SciencesImmunologyPathologyAutoimmunityImmunopathologyRheumatologyAutoantibodiesAutoimmune DiseasesAutoimmune Rheumatic DiseasesAutoimmune VasculitisSystemic Autoimmune DiseaseSystemic Lupus ErythematosusAnti-myeloperoxidase AntibodiesAnti-neutrophil Cytoplasmic AntibodiesAnti-neutrophil Cytoplasmic Antibody TestingAntineutrophil AntibodiesAntineutrophil Cytoplasmic AntibodiesAutoimmune SerologyHydralazine TherapySystemic Lupus Erythematosus Associations
Anti-neutrophil cytoplasm antibody (ANCA) has been shown to be no marker of systemic lupus erythematosus (SLE) including lupus nephritis or of progressive systemic sclerosis (PSS). Antibodies against myeloperoxidase (anti-MPO) and elastase, two granulocyte lysosomal enzymes, were found in patients with SLE but not in those with PSS, except for one patient who had anti-MPO. Anti-MPO was present in 21% of patients with SLE, and at low concentrations in about 80% of these cases. Anti-elastase was found in four patients with SLE. In another group of six patients with a SLE-like syndrome induced by anti-hypertensive treatment with the anti-hypertensive hydralazine, anti-MPO antibodies occurred in all six, and anti-elastase antibodies in five. Monitored during a 2-year follow-up period, anti-MPO antibodies were found to persist, whereas anti-elastase antibodies were rapidly eliminated, after withdrawal of the drug.
23
The 1982 revised criteria for the classification of systemic lupus erythematosus
Eng M. Tan, Alan S. Cohen, James F. Fries et al. · Arthritis & Rheumatism · 1982 · 14.6K citations
Ronald J. Falk, J. Charles Jennette · New England Journal of Medicine · 1988 · 1.4K citations
Medicine, Immunology, Pathology +17